Page last updated: 2024-08-23

cabergoline and Heart Valve Diseases

cabergoline has been researched along with Heart Valve Diseases in 70 studies

Research

Studies (70)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	36 (51.43)	29.6817
2010's	30 (42.86)	24.3611
2020's	4 (5.71)	2.80

Authors

Authors	Studies
Arastu, MI; Curiale, AM; Lipton, BA; Longo, S; Nanda, S; Tessier, S	1
Budayr, A; Go, AS; Lo, JC; Tabada, GH; Tan, TC; Yang, J; Zaroff, JG	1
Bestwick, JP; Bhattacharyya, S; Boomla, K; Drake, WM; Lloyd, G; Steeds, RP; Stiles, CE	1
Albarel, F; Amodru, V; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Graillon, T; Morange, I	1
Jobic, Y; Tribouilloy, C	1
Drake, WM; Steeds, RP; Stiles, CE	1
Caputo, C; Inder, WJ	1
Ariano, C; De Vecchis, R; Esposito, C	1
Auriemma, RS; Colao, A; Ferreri, L; Gasperi, M; Grasso, LF; Iacuaniello, D; Perone, Y; Pivonello, R; Simeoli, C	1
Bevan, JS; Drake, WM; Howlett, TA; Steeds, RP; Stiles, CE; Toogood, AA	1
Canpolat, U; Elibol, B; Ozer, N; Yorgun, H	1
Andersen, M; Dal, J; Jørgensen, JO; Kistorp, C; Laurberg, P; Mægbæk, ML; Nørrelund, H; Steffensen, C	1
Barambio-Ruíz, M; Córdoba-Soriano, JG; Hidalgo-Olivares, VM; Lamas-Oliveira, C; Salas-Nieto, J; Tercero-Martínez, A	1
Ezzat, S; Samson, SL	1
Bianchini, E; Bramanti, P; Cilia, R; Ciurleo, R; de Luise, C; Di Lorenzo, G; Ilardi, M; Italiano, D; Pezzoli, G; Polimeni, G; Rijnbeek, P; Ross, D; Stocchi, F; Sturkenboom, M; Trifirò, G; Vacca, L; Zanettini, R	1
Caputo, C; Inder, WJ; Prior, D	1
Auriemma, RS; Colao, A; Ferreri, L; Pivonello, R; Priscitelli, P	1
Anyiam, S; Baldeweg, FC; Baldeweg, SE; Bevan, JS; Butt, N; Drake, WM; Han, TS; Karavitaki, N; Kyriakakis, N; Martin, NM; Murray, RD; Parasuraman, SK; Rees, DA; Richardson, TI; Sheikh, UE; Steeds, RP; Stiles, CE; Stojanovic, N; Taylor, L; Toogood, AA; Trainer, PJ; Vaidya, B	1
Auriemma, R; Beckers, A; Daly, AF; Dulgheru, R; Garcia, MT; Lancellotti, P; Magne, J; Maiga, I; Petrossians, P; Rubio-Almanza, M; Vroonen, L	1
Bax, JJ; Delgado, V; Feelders, RA; Holman, ER; Kars, M; Pereira, AM; Romijn, JA; Smit, JW	1
Aris-Jilwan, N; Beauregard, H; Delorme, S; Garfield, N; Houde, G; Kahtani, N; Rivera, J; Santagata, P; Serri, K; Serri, O; Vallette, S	1
Atkin, SL; Clark, AL; Kallvikbacka-Bennett, A; Rigby, AS; Wakil, A	1
Bax, JJ; Kars, M; Pereira, AM; Romijn, JA	1
Hiramoto, T; Kikuchi, A; Onodera, J; Onoue, N; Oumi, M; Sato, T	1
Blevins, LS; Byrd, BF; Devin, JK; Lakhani, VT	1
Molitch, ME	1
Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C	1
Becher, H; Herring, N; Karavitaki, N; Szmigielski, C; Wass, JA	1
Andersohn, F; Garbe, E	1
Sherlock, M; Steeds, R; Toogood, AA	1
Bogazzi, F; Lombardi, M; Manetti, L; Martino, E; Raffaelli, V; Rossi, G	1
Martin, NM; Meeran, K; Tan, T	1
Pullan, PT	1
Bhattacharyya, S; Davar, J; Mikhailidis, DP; Schapira, AH	1
Cervantes, CE; Da Costa, CV; Hernando, CA; Vargas, ML	1
Serri, K; Serri, O; Vallette, S	1
Cramer, MJ; Lafeber, M; Stades, AM; Teding van Berkhout, F; Valk, GD; Zelissen, PM	1
Baynes, KC; Cabrita, IZ; Dhillo, WS; Eliahoo, J; Grogono, J; Hensman, D; Martin, NM; Meeran, K; Nihoyannopoulos, P; Robinson, S; Tan, T	1
Antonini, A; Gatto, G; Gentile, R; Pezzoli, G; Tesei, S; Zanettini, R	2
Carroll, PV; Chambers, J; Gu, H; Luck, S; Powrie, J	1
Kubota, K; Ooba, N; Yamaguchi, T	1
Ikeda, S; Ishizaki, T; Morikawa, K; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H	1
Gmeiner, P; Hübner, H; Kekewska, A; Pertz, HH	1
Bötzel, K; Levin, J; Näbauer, M; Neudert, J; Zwermann, L	1
Finestone, AJ	1
Azevedo, M; Boguszewski, CL; de Souza, AM; dos Santos, CM; Marini, LC; Sakamoto, KS	1
Ceballos-Baumann, AO; Fietzek, UM; Riedl, L	1
Elenkova, A; Kalinov, K; Shabani, R; Zacharieva, S	1
Bilge, A; Kurtulmus, N; Yarman, S	1
Assayag, P; Bouchachi, A; Chanson, P; Garcia, C; Kallel, N; Maione, L; Maison, P; Salenave, S; Young, J	1
Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H	1
Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP	1
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P	1
Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Luce, P; Medcalf, P; Odin, P; Stegie, F	1
Burger, E; Härtter, S; Kvernmo, T	1
Diaz Molina, B; Iglesias-Cubero, G; Martin, M; Moris De la Tassa, C	1
Fuhrmann, JT; Junghanns, S; Koch, R; Oelwein, C; Reichmann, H; Simonis, G; Storch, A; Strasser, RH	1
Roth, BL	1
Andersohn, F; Garbe, E; Haverkamp, W; Schade, R; Suissa, S	1
Erginöz, E; Kenangil, G; Koldas, L; Ozekmekçi, S; Sahin, T	1
Ionescu, A; Price, DE; Stephens, JW	1
Altschuler, EL; Kast, RE	1
Senol, MG; Togrol, RE	1
Fuhrmann, JT; Simonis, G; Strasser, RH	1
Antonini, A; Poewe, W	1
Belleville, I; Boujon, B; Chague, F; Petit, JM	1
Dupont, E; Egeblad, H; Poulsen, SH; Rasmussen, VG; Safikhany, G; Østergaard, K	1
Beckers, A; Betea, D; Burlacu, MC; Daly, AF; Lancellotti, P; Livadariu, E; Markov, M; Pierard, L	1

Reviews

12 review(s) available for cabergoline and Heart Valve Diseases

Article	Year
The risks of medical treatment of prolactinoma. Annales d'endocrinologie, 2021, Volume: 82, Issue:1 Topics: Cabergoline; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Fibrosis; Heart Valve Diseases; Humans; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Substance-Related Disorders	2021
Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies. Herz, 2013, Volume: 38, Issue:8 Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Myocardium; Observational Studies as Topic; Prevalence; Risk Factors	2013
[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients]. Ugeskrift for laeger, 2014, 01-06, Volume: 176, Issue:1 Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Parkinson Disease; Ultrasonography	2014
The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:11 Topics: Adult; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma	2015
Cabergoline use for pituitary tumors and valvular disorders. Endocrinology and metabolism clinics of North America, 2015, Volume: 44, Issue:1 Topics: Acromegaly; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pituitary Neoplasms; Prolactinoma	2015
Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. European journal of endocrinology, 2008, Volume: 159, Issue:4 Topics: Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pituitary Neoplasms; Prolactinoma	2008
Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. Journal of endocrinological investigation, 2008, Volume: 31, Issue:12 Topics: Aortic Valve; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Mental Disorders; Mitral Valve; Risk Factors; Tricuspid Valve	2008
Drug-induced fibrotic valvular heart disease. Lancet (London, England), 2009, Aug-15, Volume: 374, Issue:9689 Topics: Antiparkinson Agents; Appetite Depressants; Cabergoline; Dexfenfluramine; Dopamine Agonists; Drug Monitoring; Ergolines; Ergotamine; Fenfluramine; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Methysergide; Migraine Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Patient Selection; Pergolide; Receptors, Serotonin; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins; Vasoconstrictor Agents	2009
[Cabergoline in hyperprolactinemia and valvular heart disease]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2009, Volume: 56, Issue:8 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactin; Prolactinoma; Ultrasonography	2009
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clinical therapeutics, 2006, Volume: 28, Issue:8 Topics: Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Heart Valve Diseases; Humans; Indoles; Pergolide; Pulmonary Fibrosis; Receptors, Dopamine	2006
Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2007, Oct-15, Volume: 22, Issue:13 Topics: Antiparkinson Agents; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Drug Combinations; Echocardiography; Ergolines; Ergot Alkaloids; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide; Product Surveillance, Postmarketing	2007
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. The Lancet. Neurology, 2007, Volume: 6, Issue:9 Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide	2007

Trials

5 trial(s) available for cabergoline and Heart Valve Diseases

Article	Year
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. European journal of endocrinology, 2013, Volume: 169, Issue:3 Topics: Adult; Antineoplastic Agents; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Monitoring; Early Diagnosis; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Heart Valves; Humans; Italy; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Severity of Illness Index; Time Factors; Ultrasonography	2013
Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary, 2009, Volume: 12, Issue:3 Topics: Adult; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma	2009
Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clinical endocrinology, 2011, Volume: 74, Issue:5 Topics: Adult; Antineoplastic Agents; Artifacts; Bias; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Tricuspid Valve Insufficiency	2011
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Movement disorders : official journal of the Movement Disorder Society, 2007, Jan-15, Volume: 22, Issue:2 Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Hypertrophy, Left Ventricular; Indoles; Male; Middle Aged; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Tricuspid Valve Insufficiency	2007
Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease. Journal of internal medicine, 2008, Volume: 263, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Cabergoline; Cross-Sectional Studies; Denmark; Dopamine Agonists; Electrocardiography; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Logistic Models; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Ultrasonography	2008

Other Studies

53 other study(ies) available for cabergoline and Heart Valve Diseases

Article	Year
Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy. Echocardiography (Mount Kisco, N.Y.), 2023, Volume: 40, Issue:1 Topics: Bromocriptine; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Middle Aged; Pituitary Neoplasms	2023
Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC endocrine disorders, 2020, Feb-19, Volume: 20, Issue:1 Topics: Adult; Cabergoline; California; Cross-Sectional Studies; Dopamine Agonists; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Prognosis; Young Adult	2020
Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints. The Journal of clinical endocrinology and metabolism, 2021, 01-23, Volume: 106, Issue:2 Topics: Adult; Biomarkers; Cabergoline; Case-Control Studies; Cohort Studies; Echocardiography; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Incidence; London; Male; Middle Aged; Pituitary Neoplasms; Primary Health Care; Prolactinoma	2021
[Drug-induced valve heart disease]. La Revue du praticien, 2016, Volume: 66, Issue:8 Topics: Cabergoline; Dopamine Agonists; Heart Valve Diseases; Humans; Pergolide	2016
Response to Letter to the Editor: "A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline". The Journal of clinical endocrinology and metabolism, 2019, 10-01, Volume: 104, Issue:10 Topics: Cabergoline; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Prevalence	2019
Letter to the Editor: "A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline". The Journal of clinical endocrinology and metabolism, 2019, 10-01, Volume: 104, Issue:10 Topics: Cabergoline; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Prevalence	2019
A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:1 Topics: Adult; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Prevalence; United Kingdom	2014
Evaluation of the valvular and biventricular functions in Parkinson patients using ergotamine-derived dopamine agonist: an observational study. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2014, Volume: 14, Issue:2 Topics: Cabergoline; Cohort Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease	2014
Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline. Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:5 Topics: Adult; Cabergoline; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged	2013
AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2014, Volume: 20, Issue:6 Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Risk	2014
Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:6 Topics: Aged; Antiparkinson Agents; Cabergoline; Cohort Studies; Echocardiography; Ergolines; Female; Guideline Adherence; Heart Valve Diseases; Heart Valves; Humans; Incidence; Italy; Male; Middle Aged; Parkinson Disease; Pergolide; Practice Guidelines as Topic; Prevalence; Retrospective Studies; Risk Factors; Supranuclear Palsy, Progressive	2015
A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:11 Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Prevalence; United Kingdom	2016
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine, 2017, Volume: 55, Issue:1 Topics: Adult; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Prospective Studies; Treatment Outcome; Young Adult	2017
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:9 Topics: Adult; Aortic Valve; Cabergoline; Calcinosis; Case-Control Studies; Cross-Sectional Studies; Disease Progression; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Time Factors; Tricuspid Valve Insufficiency	2008
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European journal of endocrinology, 2008, Volume: 159, Issue:4 Topics: Adult; Cabergoline; Cross-Sectional Studies; Databases, Factual; Dopamine Agonists; Echocardiography; Echocardiography, Doppler, Color; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Risk Factors	2008
[Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline]. Rinsho shinkeigaku = Clinical neurology, 2008, Volume: 48, Issue:7 Topics: Aged; Antiparkinson Agents; Cabergoline; Ergolines; Fatal Outcome; Female; Heart Failure; Heart Valve Diseases; Humans; Parkinson Disease	2008
Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2008, Volume: 14, Issue:6 Topics: Adult; Cabergoline; Cohort Studies; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Middle Aged	2008
The cabergoline-resistant prolactinoma patient: new challenges. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:12 Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine; Young Adult	2008
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:2 Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors	2009
Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical endocrinology, 2009, Volume: 70, Issue:1 Topics: Aortic Valve Insufficiency; Cabergoline; Calcinosis; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma; Ventricular Dysfunction, Left	2009
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1 Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States	2009
Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart (British Cardiac Society), 2009, Volume: 95, Issue:7 Topics: Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Parkinson Disease; Pergolide; Tricuspid Valve Insufficiency	2009
Dopamine agonists and hyperprolactinaemia. BMJ (Clinical research ed.), 2009, Mar-03, Volume: 338 Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia	2009
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy. Internal medicine journal, 2009, Volume: 39, Issue:4 Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography	2009
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert review of cardiovascular therapy, 2010, Volume: 8, Issue:1 Topics: Adult; Cabergoline; Case-Control Studies; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2	2010
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. European journal of endocrinology, 2010, Volume: 162, Issue:4 Topics: Acromegaly; Blood Sedimentation; C-Reactive Protein; Cabergoline; Creatinine; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Electrocardiography; Ergolines; Female; Fibrosis; Glomerular Filtration Rate; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Lung; Lung Diseases; Male; Middle Aged; Respiratory Function Tests; Retroperitoneal Fibrosis; Statistics, Nonparametric	2010
Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clinical endocrinology, 2010, Volume: 73, Issue:3 Topics: Adult; Antiparkinson Agents; Blood Pressure; Cabergoline; Cross-Sectional Studies; Dose-Response Relationship, Drug; Echocardiography; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies; Risk Assessment; Ventricular Function, Left; Ventricular Function, Right	2010
Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovascular therapeutics, 2011, Volume: 29, Issue:6 Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Heart Valve Diseases; Humans; Italy; Male; Middle Aged; Parkinson Disease; Patient Selection; Pergolide; Prevalence; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Ultrasonography	2011
The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Drug safety, 2011, Apr-01, Volume: 34, Issue:4 Topics: Cabergoline; Databases, Factual; Dopamine Agonists; Drug Prescriptions; Drug Utilization Review; Ergolines; Government Regulation; Heart Valve Diseases; Humans; Insurance Claim Review; Japan; Legislation, Drug; Parkinson Disease; Pergolide; Regression Analysis; Ultrasonography	2011
Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:7 Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Drug Labeling; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Incidence; Japan; Male; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Risk Factors	2011
The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease. The Journal of pharmacology and experimental therapeutics, 2011, Volume: 338, Issue:1 Topics: Animals; Cabergoline; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Ergolines; Heart Valve Diseases; Humans; Pulmonary Artery; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Serotonin Receptor Agonists; Swine	2011
Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease. Journal of neurology, 2011, Volume: 258, Issue:11 Topics: Antiparkinson Agents; Cabergoline; Echocardiography, Doppler, Color; Ergolines; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Parkinson Disease	2011
Adverse drug reaction suggested by a clinical vignette. Clinical interventions in aging, 2011, Volume: 6 Topics: Antineoplastic Agents; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans	2011
A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary, 2012, Volume: 15, Issue:1 Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma	2012
Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline. Parkinsonism & related disorders, 2012, Volume: 18, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Cohort Studies; Cross-Sectional Studies; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Odds Ratio; Parkinson Disease; Retrospective Studies; Risk Assessment	2012
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. European journal of endocrinology, 2012, Volume: 167, Issue:1 Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Prospective Studies	2012
Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas. Neuro endocrinology letters, 2012, Volume: 33, Issue:3 Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Retrospective Studies; Risk Factors; Ultrasonography; Young Adult	2012
No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9 Topics: Acromegaly; Adolescent; Adult; Aged; Aortic Valve Insufficiency; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Echocardiography, Doppler; Ergolines; Female; Heart Valve Diseases; Heart Valves; Humans; Hypertrophy, Left Ventricular; Longitudinal Studies; Male; Middle Aged; Mitral Valve Insufficiency; Retrospective Studies; Tricuspid Valve Insufficiency; Young Adult	2012
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:6 Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide	2004
Cardiopulmonary complications of ergot-derivative dopamine agonists. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:10 Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone	2004
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:12 Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide	2004
Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Retrospective Studies	2005
Mitral heart disease due to cabergoline. International journal of cardiology, 2007, Jan-02, Volume: 114, Issue:1 Topics: Antiparkinson Agents; Cabergoline; Ergolines; Female; Heart Valve Diseases; Humans; Middle Aged; Mitral Valve Insufficiency	2007
Drugs and valvular heart disease. The New England journal of medicine, 2007, Jan-04, Volume: 356, Issue:1 Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Pergolide; Receptor, Serotonin, 5-HT2B; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists	2007
Dopamine agonists and the risk of cardiac-valve regurgitation. The New England journal of medicine, 2007, Jan-04, Volume: 356, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Case-Control Studies; Cohort Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Logistic Models; Male; Middle Aged; Parkinson Disease; Pergolide; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists	2007
Valvular heart disease and the use of dopamine agonists for Parkinson's disease. The New England journal of medicine, 2007, Jan-04, Volume: 356, Issue:1 Topics: Aged; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Parkinson Disease; Pergolide; Regression Analysis; Risk; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Ultrasonography	2007
Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clinical neurology and neurosurgery, 2007, Volume: 109, Issue:4 Topics: Aged; Antiparkinson Agents; Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies; Tricuspid Valve Insufficiency	2007
Parkinson's drugs linked to heart valve trouble. Harvard heart letter : from Harvard Medical School, 2007, Volume: 17, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Pergolide	2007
Dopamine agonists and valvular heart disease. The New England journal of medicine, 2007, Apr-19, Volume: 356, Issue:16 Topics: Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Ventricular Remodeling	2007
Dopamine agonists and valvular heart disease. The New England journal of medicine, 2007, Apr-19, Volume: 356, Issue:16 Topics: Antipsychotic Agents; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Methysergide; Pergolide; Receptor, Serotonin, 5-HT2B; Retroperitoneal Fibrosis; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists	2007
Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology, 2007, Jul-03, Volume: 69, Issue:1 Topics: Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Parkinson Disease; Patient Selection; Pergolide; Pramipexole; Research Design; Sex Factors	2007
[Aortic insufficiency under weak doses of cabergoline for non-tumoral hyperprolactinemia]. Annales d'endocrinologie, 2007, Volume: 68, Issue:6 Topics: Aortic Valve Insufficiency; Cabergoline; Diagnosis, Differential; Dopamine Agents; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Middle Aged; Receptor, Serotonin, 5-HT2B	2007
Cabergoline and the risk of valvular lesions in endocrine disease. European journal of endocrinology, 2008, Volume: 159, Issue:1 Topics: Adult; Aged; Cabergoline; Cross-Sectional Studies; Dopamine Agonists; Echocardiography; Endocrine System Diseases; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Risk Factors	2008